Game Changer: Novo Nordisk Rolls Out Once-Weekly Awiqli Insulin in India

In a major leap for diabetes care, Danish pharmaceutical giant Novo Nordisk has just launched Awiqli, the world's first once-weekly basal insulin, in India. Rolled out on July 9, 2026, this groundbreaking injection, known generically as Insulin icodec, aims to dramatically cut down the number of annual insulin shots from 365 to a mere 52, easing the burden for millions of adult patients with Type 1 and Type 2 diabetes across the nation. This move is set to reshape diabetes management, offering much-needed convenience and potentially boosting treatment adherence in a country grappling with a soaring diabetes epidemic. India is home to over 101 million people living with diabetes and another 136 million with prediabetes, making it one of the countries with the highest diabetes rates globally. A significant challenge has been the reluctance of patients to start insulin therapy, often delayed by 7-9 years due to the fear of daily injections, perceived pain, and cost concerns. Novo Nordisk India Managing Director Vikrant Shrotriya highlighted that Awiqli competitive pricing – a weekly dose costs around ₹261, potentially cheaper than existing daily basal insulin products – combined with its simplified regimen, is designed to overcome these barriers and potentially double the current 6-7 million insulin users in India. The introduction of Awiqli, which has already received approvals in the U.S. and Europe, marks India as either the sixth or seventh country globally to receive this advanced therapy, solidifying India's crucial role in Novo Nordisk global strategy. The drug will be rolled out in the market next week and is expected to face competition from established daily basal insulin brands like Sanofi's Lantus and more affordable insulin glargine products from local manufacturers. This launch sets the stage for a new era in chronic disease management, where innovation focused on patient convenience could drive better health outcomes and market shifts in India's rapidly growing pharmaceutical landscape.